79491-46-6

Basic information

• Product Name: 2,6-dibroMo-3-Methoxy-5-nitropyridine
• Synonyms: 2,6-dibroMo-3-Methoxy-5-nitropyridine
• CAS NO: 79491-46-6
• Molecular Formula: C6H4Br2N2O3
• Molecular Weight: 311.91556
• Mol File: 79491-46-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 113-114 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 342.5±37.0 °C(Predicted)
• Appearance: /
• Density: 2.067±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -12.06±0.10(Predicted)
• CAS DataBase Reference: 2,6-dibroMo-3-Methoxy-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dibroMo-3-Methoxy-5-nitropyridine(79491-46-6)
• EPA Substance Registry System: 2,6-dibroMo-3-Methoxy-5-nitropyridine(79491-46-6)

Safety Data

• Hazardous Substances Data: 79491-46-6(Hazardous Substances Data)

Usage

General Description

2,6-dibromo-3-methoxy-5-nitropyridine, also known as DBMP, is a chemical compound with the molecular formula C6H4Br2N2O3. It is a yellow crystalline solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. DBMP is a nitroaromatic compound with two bromine atoms and a methoxy group attached to a pyridine ring. It is primarily used in the production of pharmaceuticals and is also utilized as a building block for the synthesis of various organic compounds. This chemical is toxic if ingested or inhaled and may cause irritation to the skin, eyes, and respiratory system, so precautionary measures should be taken when handling and storing it.

Upstream product

• 79491-45-5 2,6-dibromo-3-methoxylpyridine 
• 109-00-2 3-HYDROXYPYRIDINE 
• 6602-33-1 2,6-dibromopyridin-3-ol 

Downstream Products

• 64436-92-6 3-amino-5-methoxypyridine 
• 79491-47-7 2,6-dibromo-5-methoxypyridin-3-amine 
• 79491-48-8 2-bromo-5,6-dimethoxy-3-nitropyridine 
• 79491-49-9 3-amino-5,6-dimethoxypyridine 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula I'. Compounds of Formula I' inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase- dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.

Synthetic Uses of the Sequential Ring Positional Reactivity in Pyridin-3-ol and Derivatives

A series of ring-substituted pyridin-3-ols has been prepared.The key to the scheme is the introduction of a bromo group to a specific ring position as a temporary blocking agent.As well as hydrogenolysis of the bromo function, nucleophilic displacement has also been investigated.